Abstract
No public abstract is available from the verified source records.
Julien Moragny, Emeline Delabre, Florine Foré, Youssef Bennis, Valérie Gras, Mohamad Houssam Al Balkhi
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Infliximab, azathioprine, or combination therapy for Crohn’s disease
10.1056/nejmoa0904492 · 2010
Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations
10.1016/j.cgh.2009.07.019 · 2009
Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes
10.1002/cpt.1304 · 2019
HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
10.1002/pbc.21039 · 2007
Risk factors for thiopurine-induced leukopenia in IBD: a systematic review and meta-analysis
10.1111/apt.15403 · 2019
Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease
10.1001/jama.2019.0709 · 2019
Unresolved referenced work
Kept as external metadata until matched
Association of ITPA gene polymorphisms with adverse effects of azathioprine and 6-mercaptopurine therapy: a systematic review and meta-analysis
10.1038/s41397-021-00255-3 · 2022
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients
datacite
Confidence 0%
10.1038/s41397-024-00341-2 · 2024
No additional external references are available.